Table 1.

Prognostic autoantibodies in Sjögren’s syndrome

Autoantibodies	Prevalence, %	Properties	Clinical association
Anti-Ro/SSA	50–70	Disease marker in healthy	Younger age, extraglandular
		Lymphoma predictive model
Anti-La/SSB	25–40	Disease marker in healthy	Extraglandular
		Lymphoma predictive model
Rheumatoid factor	36–74	Phenotype marker	Anti-Ro/La, extraglandular
		Lymphoma predictive model
Anti-CCP	3–10	Phenotype marker	Arthritis
AMA	3–10	Phenotype marker	Elevated liver enzymes, PBC
ACA	3–27	Phenotype marker	Raynaud’s phenomenon
Cryoglobulins	3–12	Phenotype marker	lymphoma, extraglandular
		Lymphoma predictive model

Anti-Ro/SSA and anti-La/SSB are associated with systemic disease with anti-Ro part of the most recent classification criteria. Other autoantibodies are important for neither diagnosis nor research classification but identify Sjögren’s syndrome patients with certain clinical features.CCP, citrullinated cyclic peptide; AMA, anti-mitochondrial antibody; ACA, anti-centromere antibody; PBC, primary biliary cholangitis.